Clinical Trial Update: Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) [Phase 3]

View source ↗

Summary

AbbVie is conducting a long-term extension Phase 3 study to assess the safety and tolerability of oral ubrogepant for the acute treatment of migraine in pediatr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ubrogepant (ubrogepant)

Snippet

Sponsor: AbbVie | Conditions: Migraine | Phase 3 | Status: ENROLLING_BY_INVITATION